RxDoctor Payments Data

Maria Courser, MD

Internal Medicine · Columbus, OHNPI 1275544611

Payments from drug & device makers

$472in general payments, 2019–2025

Across 31 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$90
  • Merck$67
  • Johnson & Johnson$56
  • Lilly USA, LLC$41
  • Takeda Pharmaceuticals U.S.A., Inc.$39
  • Amarin Pharma, Inc.$34
  • plus $145 from 8 others

What the payments were for

  • Food & beverage$472100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$472 in reported general payments places this provider in the 65th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$64,327
Medicare patients
134
Services billed
621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$56,386
JanuviaSitagliptin Phosphate41$37,242
Tresiba Flextouch U-100Insulin Degludec27$33,868
MounjaroTirzepatide25$33,776
XareltoRivaroxaban26$29,774
Breo ElliptaFluticasone/Vilanterol26$19,627
FarxigaDapagliflozin Propanediol21$18,275
EntrestoSacubitril/Valsartan13$11,595
SymbicortBudesonide/Formoterol Fumarate26$6,808
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$4,738
Humalog Kwikpen U-100Insulin Lispro13$4,050
SynthroidLevothyroxine Sodium49$3,929
VyvanseLisdexamfetamine Dimesylate11$3,884
Atorvastatin Calcium276$3,453
Valsartan99$3,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$56,38663 claims
MerckJanuvia$67$37,24241 claims
Lilly USA, LLCMounjaro$41$33,77625 claims
Johnson & JohnsonXarelto$56$29,77426 claims
AstraZenecaFarxiga, Symbicort$13$25,08347 claims
GSKBreo Ellipta$14$19,62726 claims
AbbVieSynthroid$28$3,92949 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$39$3,88411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →